In breast cancer cells PRL confers resistance against cisplatin by activating a detoxification enzyme [48,49] and in ovarian carcinoma cells PRL and its receptor inhibit apoptosis induced by serum starvation or cisplatin treatment [49]. The gene discussed is PRL; the disease is breast cancer.